CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 99 enrolled
Drug / intervention
Tildrakizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03897075
NCT03897075Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

Sun Pharmaceutical Industries Limited·interventional·Posted Apr 1, 2019·Updated Apr 1, 2026

In Brief

A Phase 3 clinical trial evaluating Tildrakizumab and Placebo for Chronic Plaque Psoriasis and Moderate to Severe Nail Psoriasis. Completed, enrolled 99 participants across 17 sites in 2 countries.

Detailed Summary

Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
CountriesAustralia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 1, 2019
Enrollment StartMay 13, 2021
Primary CompletionApr 5, 2024
Study CompletionJan 30, 2025
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.3 years ago

Interventions

Tildrakizumabdrug

PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up

Placebodrug

PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up